Failure of yttrium-90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (Zevalin®) with fatal side effects in relapsed/refractory diffuse large B-cell NHL transformed from other lymphomas
Songül Şerefhanoğlu,
Ebru Koca,
Hakan Goker,
İbrahim Celalettin Haznedaroğlu,
Deniz Çetiner,
Nilgün Sayınalp,
Yahya Büyükaşık,
Osman İlhami Özcebe
Affiliations
Songül Şerefhanoğlu
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey
Ebru Koca
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey
Hakan Goker
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey
İbrahim Celalettin Haznedaroğlu
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey
Deniz Çetiner
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey
Nilgün Sayınalp
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey
Yahya Büyükaşık
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey
Osman İlhami Özcebe
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey
